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Abstract
Background: Industry commissions contracting companies to perform network meta-analysis for health technology
assessment (HTA) and reimbursement submissions. Our objective was to estimate the number of network meta-
analyses performed by consulting companies contracted by industry, to assess whether they were published, and
to explore reasons for non-publication.
Methods: We searched MEDLINE for network meta-analyses of randomized trials. Papers were included if they had
authors affiliated with any contracting company. All identified contracting companies as well as additional ones
from the list of the exhibitors at the International Society for Pharmacoeconomics and Outcomes Research, an
annual meeting that representatives from many contracting companies attend and exhibit at, were surveyed
regarding conduct and publication of network meta-analyses.
Results: In 162 of 822 (20%) network meta-analysis papers, authors were affiliated to 66 contracting companies.
Another 36 contracting companies were identified by the exhibitors list. Three companies had no contact
information and six merged with others, therefore 93 companies were contacted. Thirty seven out of ninety three
(40%) companies responded, and 19 indicated that they had performed a total of 476 network meta-analyses, but
only 102 (21%) papers were published.
Thirteen companies that disclosed to have conducted 174 network meta-analyses (45 published) provided reasons
for non-publication. Of the 129 still unpublished meta-analyses, for 40 there were plans for future publication, for 37
the sponsor did not allow publication, for 16 the contracting companies did not plan to publish the meta-analysis,
for another 23 plans were unclear, and the remaining 13 were used as HTA submission.
The protocol of the network meta-analysis was publically available from 11/162 (6.8%) network meta-analyses
published by authors affiliated with contracting companies.
Conclusions: There is a prolific sector of professional contracting companies that perform network meta-analyses.
Industry commissions many network meta-analyses, but most are not registered before or published after analyses
in the scientific literature. Mechanisms to improve publication rates of network meta-analysis commissioned by
industry are warranted.
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Background
For many clinical conditions, multiple treatment options
are assessed in randomized trials. Using network meta-
analysis, it is possible to assess the comparative effective-
ness of multiple interventions using both direct and
indirect evidence [1–3]. Network meta-analyses are particu-
larly useful for clinical guideline development and policy,
and to quantify relative treatment effects (and eventually
ranking multiple treatments options for efficacy and/or
safety) and the uncertainty around these effects in order to
inform cost-effectiveness analyses (CEA) and therefore
healthcare resource allocation decisions. Development of
methods for and the use of network meta-analysis has been
strongly driven by regulatory requirements of health tech-
nology assessment (HTA) and reimbursement submissions
in general and CEA in particular, as HTA requires the com-
parison of a novel drug against a broad range of marketed
comparators to ensure that the therapies with the most
favourable benefit/risk profile reach patients and that lim-
ited healthcare resources are appropriately invested. Add-
itionally, these requirements initiated the development of
an industry of people conducting these studies in private
firms, so-called contracting consulting companies. These
contracting companies are commissioned by biotech and
pharmaceutical industry to conduct network meta-analysis
to facilitate HTA and reimbursement submissions to agen-
cies such as the National Institute for Health and Care Ex-
cellence (NICE) or Canadian Agency for Drugs and
Technologies in Health (CADTH).
Network meta-analysis has grown rapidly, especially over
the last few years [4]. An increasing number of contracting
consulting companies undertake meta-analyses and several
of them perform also network meta-analyses. The exact ex-
tent of this phenomenon has not been systematically stud-
ied. It would be interesting to understand who performs
these analyses and how they get disseminated or not in the
literature. We anticipate that many more meta-analyses,
and network meta-analyses in particular, have been con-
ducted than those published. In commissioned analyses,
non-publication may occur for several reasons, including
but not limited to unfavorable results for the manufacturer,
unwillingness to share with the public (and thus also with
competitors) private information and/or information that
they consider important to give them insights and strategic
advantages, low priority for publication for meta-analysis
topics that might have already been covered in other pub-
lished papers, or simply no strong incentives for the manu-
facturer (i.e., in the form of regulation) or contracting
company to publish the results.
The goal of this study was to determine the amount of
network meta-analyses performed by consulting compan-
ies contracted by industry. At a second stage, we aimed
also to explore whether the results of these meta-analyses
were published and, if not, why they remain unpublished.
Methods
Strategy
Network meta-analyses can be performed by contracting
companies commissioned by the industry to perform
this work. Two searches were performed to identify
these contracting companies. Afterwards, these compan-
ies were sent surveys with questions related to the num-
ber of performed network meta-analyses, number
published, and reasons for non-publication.
Identification of contracting companies: sources and
searches
First, MEDLINE was searched for network meta-
analyses from inception until 6 May 2015. We used the
following search strategy: “(network [tiab] AND (meta
analys*[tiab])) OR indirect comparison*[tiab] OR indir-
ect treatment comparison*[tiab] OR multiple treatment
comparison*[tiab] OR mixed treatment comparison*[-
tiab]”. No language restrictions were used. Papers
were considered potentially eligible if they described a
network meta-analysis of randomized clinical trials.
We did not exclude papers that apart from random-
ized clinical trials also included quasi-randomized
clinical trials or papers in which they combined data
from observational studies and randomized clinical
trials. Papers describing non-intervention studies, letters
to the editor, editorials, protocols, reviews, and papers de-
scribing methodology were excluded. Papers that used a
network meta-analysis to assess cost-effectiveness but not
clinical effectiveness or safety were also excluded. The po-
tentially eligible papers were scored by one author (ES)
based on the affiliations of the authors for being con-
ducted by academia (university or hospital), industry (bio-
tech or pharmaceutical company), contracted consulting
company, or a combination.
Second, the list of the exhibitors at the 20th Annual
International Meeting (May 2015) of the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) was searched for contracting companies [5].
The ISPOR is an international multidisciplinary profes-
sional membership society, that aims to advance the pol-
icy, science, and practice of pharmacoeconomics (health
economics) and outcomes research (the scientific discip-
line that evaluates the effect of health care interventions
on patient well-being including clinical, economic, and
patient-centered outcomes). As such, many professionals
from academia, industry, and consulting companies at-
tend ISPOR meetings, and many (consulting) companies
have exhibitions to promote their companies and to re-
cruit personnel and attract new customers. For those
companies of the ISPOR list for which it was unclear
whether they perform network meta-analysis, inclusion
was based on the information on the company’s website
(identified through Google by ES).
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No further selection of contracting companies oc-
curred. The company was considered for further study if
a person affiliated to a contracting company co-authored
a published network meta-analysis or if their company
website indicated that they did perform network meta-
analysis.
Data collection via surveys
Identified contracting companies from both searches were
contacted by e-mail or through a contact form on the
company’s website if an e-mail address was not available.
Companies were surveyed and asked: (1) has your com-
pany ever undertaken any network meta-analyses, and if
so, (2) when did your company first perform a network
meta-analysis, (3) how many network meta-analyses have
been completed by your company to date, where a net-
work meta-analysis referred to a commissioned network
meta-analysis (which may in fact include more than one
network meta-analysis, e.g. for different outcomes, or sub-
groups), (4) how many of these completed network meta-
analyses have been published in the literature, (5) if they
could list references of network meta-analyses that were
published? If we had identified network meta-analyses
through our literature search we sent the company the
reference (s) of the paper (s) and asked whether they could
list any additional papers. Each company was informed
that we planned to publish the results and was allowed to
have their company’s name be de-identified in the publica-
tion, if they wished so. Companies were contacted three
times with e-mails sent 2 weeks apart. For companies that
were now part of another company, we contacted the
mother company to provide information about the former
company. When representatives responded that they had
no time to provide an exact number of conducted and
published network meta-analyses they were allowed to
give an estimate. Papers that were quoted as “published”
according to the companies but were in fact conference
abstracts (N = 23 meta-analyses), no network meta-
analysis (N = 4), cost-effectiveness analysis (N = 2), or a
methodological paper (N = 2) were not considered as pub-
lished network meta-analyses.
After collection of the data on this survey, we sent out
an additional survey to those companies that had
responded that they do perform network meta-analysis.
Here, we asked for specific reasons of network meta-
analyses not being published: (1) paper was submitted
but has been rejected, no plan to resubmit, (2) paper
was submitted, but has been rejected, still trying to pub-
lish, (3) paper was submitted and is under peer review
(first submission), (4) paper will be submitted in the fu-
ture, (5) no plan to publish the network meta-analysis,
(6) not allowed by the pharma sponsor to publish the
network meta-analysis, or (7) other reason (specify).
Again, companies were contacted three times with e-
mails sent 2 weeks apart and conference abstracts were
not considered published papers and were considered
not published with reason “unclear”.
Papers that we initially did not assign to a contracting
company because none of the authors on the paper had
the company’s affiliation (N = 9), but that which were
listed by a company were included in the total number of
published papers by that company. Additionally, papers
that we did assign to a company based on author affilia-
tions in the publication, but that were not listed by the
company itself in its reply (N = 29) were also included in
the total number of published papers by that company.
For network meta-analyses with a contracting com-
pany affiliation, we investigated whether a protocol was
publically available. The protocol could either be refer-
enced to in the paper or could be identified through
PROSPERO [6] or the website of the journal of publica-
tion, reimbursement agency, or research institute. We
also looked at protocol availability of network meta-
analyses published 1 year after the launch of PROSPERO
(Feb 2011) [7] to take into account the lower awareness
of the value of registry of systematic reviews and meta-
analyses before their launch.
Data analysis
Data analysis was descriptive. Quantitative data are pre-
sented with median and interquartile ranges and cat-
egorical data with number and percentages.
Results
Identification of contracting companies
The search, study selection, and identification of eligible
contracting companies are presented in Fig. 1.
Through our database search, we identified 2483 papers
of which 822 presented a network meta-analysis based on
title and abstract screening. Authors were affiliated to a
contracting company in 162 (20%). Contracting company
affiliations were rarely the sole affiliations of the authors of
these network meta-analyses; typically, the papers had also
authors affiliated to industry or academia or both. In 35 pa-
pers (22%), at least one of the authors with a contracting
company affiliation also had an academic affiliation, and in
one paper, two authors had both a contracting company
and industry affiliation. From this literature search, 66 con-
tracting companies were identified.
The list of exhibitors at the 2015 Annual Meeting of
ISPOR contained 89 listings, and of those, 50 (36 not
already identified by the literature search) were identified
as eligible for inclusion in our study.
A total of 102 contracting companies were thus identified
(see Additional file 1). For three companies, no contact in-
formation was available, including one company that was
dissolved. Another six companies were incorporated into
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other companies, leaving 93 eligible contracting companies
for inclusion in the e-mail survey.
Survey
Thirty-seven out of 93 contacted contracting companies
(40%) responded to our first survey (Fig. 2). Twenty-nine
responded fully, and 19 indicated they had performed
network meta-analysis. The 19 companies that responded
to our survey were involved in 89 of the 162 network
meta-analysis papers that we had identified upfront. These
19 companies were actually involved in 102 published net-
work meta-analysis papers (the 89 we identified, plus
another 13 provided to us by the companies—two papers
not indexed in PubMed, two not identified by our search,
and nine where the publication did not have a contracting
company affiliation, but which nevertheless were claimed
by the company). Four of the 102 papers had authors from
two contracting companies each.
Fig. 1 Flow diagram of identification of network meta-analyses and of contracting companies
Fig. 2 Flow diagram for contracting companies based on the replies to the first survey
Schuit and Ioannidis Systematic Reviews  (2016) 5:198 Page 4 of 8
First survey
The replies of the 19 companies to our first survey
are presented in Table 1. The experience of the com-
panies with these analyses differed largely as indicated
by the starting date of first network meta-analysis
(range: June 2000—Sept 2013) and the number of
network meta-analyses that they claimed to have per-
formed (range: 1—100). Together the 19 companies
made claims to the performance of a total of 476
network meta-analyses. The number of independent
network meta-analyses may be slightly smaller, since
some of those may have involved more than one con-
tracting company. Four companies gave an estimate
of the number of conducted network meta-analyses
rather than an exact number. The average number of
conducted network meta-analyses per year per com-
pany was 6.6 for the total sample, but varied widely
between companies (range 0.16–36).
Companies provided evidence that they had pub-
lished between 0 and 33 network meta-analyses each
for a sum of 106 (102 independent papers, four pa-
pers were co-authored by two companies). The ratio
of 106 publication contributions versus 476 claims of
network meta-analyses conducted is 0.22 and the
proportion of published vs. conducted network meta-
analyses varied widely between companies (range 0–
1.08), with one company for which we found more
published than claimed conducted network meta-
analyses (13 vs. 12; ratio published/conducted = 1.08).
The overall number of network meta-analyses pub-
lished per year was 1.5 and was found to vary also
widely between companies (range 0–3.6).
Second survey
Sixteen out of 19 companies replied to our second sur-
vey. Of these, two companies did not keep specific infor-
mation about publication status, and one company
Table 1 Results of the 19 contracting companies that indicated that they perform network meta-analysis












1 Mapi Group (incl. Health Technology Analysts
and Optum)
Nov-05 88 33 9.5 3.6 0.38
2 Abacus International/Decision Research Group Jun-07 54 10 7.0 1.3 0.19
3 Redwood Outcomes (now part of Precision
Health Economics)
Sept-13 51 5 36 3.5 0.10
4 Evidera/UBCc Nov-08 50 3 8.0 0.48 0.06
5 Kleijnen Systematic Reviews Ltdc Jan-08 20 14 2.8 2.0 0.70
6 Amaris Jan-12 15 1 4.9 0.32 0.07
7 Symmetron Ltd Nov-08 13 2 2.1 0.32 0.15
8 RTI Health Solutions Jun-00 12 13 0.82 0.89 1.08
9 Medignition Inc. Aug-08 6 6 0.92 0.92 1.00
10 Augmentium Pharma Consulting Jan-05 5 4 0.50 0.40 0.80
11 AHEAD Jun-10 2 2 0.43 0.43 1.00
12 Xintera Consulting Jan-09 2 2 0.33 0.33 1.00
13 CEMKA-EVAL May-12 2 0 0.73 0.0 0.0
14 McMDC Ltd Sep-09 2 1 0.37 0.18 0.50
15 Pharmacoeconomics and Outcomes Research
Iberia
Jan-10 2 1 0.39 0.20 0.50
16 BeSyRe Bekkering Systematic Reviews May-10 1 1 0.21 0.21 1.00
17 David Hoaglin (consulting statistician) Jan-09 1 1 0.16 0.16 1.00
18 Company 1c NP NP NP NP NP 0.04
19 Company 2c NP NP NPa NP NP 0.08
Total – 476b 106b 6.6 1.5 0.22
Companies are sorted based on the number of network meta-analyses (NMA) conducted
NP not presented due to confidentiality
aSince no list of references was available from Company 2, we used the number of papers identified by our literature search
bMeta-analyses conducted or published by more than one contracting company are double-counted, but these are uncommon. The sum of 106 for published
network meta-analyses corresponds to 102 papers, because four meta-analyses were co-authored by two contracting companies. The exact level of redundancy
for conducted meta-analyses is not correct, but is likely to be similarly low
cThese companies gave an approximation for the number of conducted network meta-analyses. For calculations the approximation was considered as the actual
number of network meta-analyses
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indicated they had no time to complete the survey. To-
gether with the three companies that did not respond,
these six were responsible for 302 (63%) out of the total
476 conducted network meta-analyses.
Based on the replies by the 13 companies that did pro-
vide reasons for non-publication, 45 out of 174 (26%)
conducted network meta-analyses had already been pub-
lished. Up to another 40 network meta-analyses max-
imum could perhaps be published in the near future, as
the authors indicated they were or would be pursuing
plans for publication: two meta-analyses had already
been submitted but were not published yet but the com-
pany indicated they were still trying to publish, 10 were
currently under review, and the company indicated plans
for future publication for another 28 meta-analyses. Two
meta-analyses had been submitted, but were rejected
and the company indicated no future plans to pursue
publication. The sponsor was claimed to be responsible
for not allowing publication of 37/129 non-published
network meta-analyses. For another 14 meta-analyses,
there was no plan to publish, but the reason was not
stated. A further 13 meta-analyses had been used for
health technology assessment (HTA) submissions to re-
imbursement agencies with unclear plans for further
publication in the scientific literature. Finally, for 23
meta-analyses it was unclear whether there was a plan to
publish them or not. When we added the 302 network
meta-analyses conducted by the six companies that did
not respond to our second survey, the reason for non-
publication was unclear in (23 + 241)/476 (55%) of all
meta-analyses. The proportion of published network
meta-analyses in companies that provided reasons for
non-publication was not significantly different from
those that did not respond (45/174 (26%) vs. 61/302
(20%), p = 0.15 by chi-square test).
Protocol availability
Of the 162 network meta-analyses with one or more au-
thors affiliated with a contracting company, 10 (6.2%) re-
ferred to a protocol, 33 (20%) mentioned a protocol was
drafted but did not provide a reference, and 119 (73%)
did not refer to or mention a protocol in their paper.
When limited to network meta-analyses published after
Feb 2012 (1 year after the launch of PROSPERO), these
numbers changed to 10 (9.1%), 23 (21%), and 77 (70%),
respectively, out of 110 network meta-analyses. Overall,
we managed to identify and access the protocol of 11
(6.8%) network meta-analyses. Three were available
through PROSPERO (all stage of review “ongoing”), five
through the National Institute for Health Research
(NIHR) of which one was also registered in PROSPERO,
two through the Agency for Healthcare Research and
Quality (AHRQ), and one each through the Cochrane
Collaboration, and the National Institute for Health and
Care Excellence (NICE). One network meta-analysis
used a company website of the York Health Economics
Consortium (YHEC) to refer to the protocol, but the
website was no longer available. All published network
meta-analyses with a publically available protocol had at
least one co-author with a sole academic affiliation. For
one network meta-analysis, the protocol was published
after the date of the last search listed in the paper (July
13, 2011 (AHRQ website protocol) vs. Jan 2011 (AHRQ
website research review)). Publication of the final paper
did occur after the publication date of the protocol
(December 5, 2011).
Discussion
Overall, our evaluation found a total of 102 companies
that provide consultancy in evidence synthesis. Nineteen
of these contracting companies replied to our first sur-
vey disclosing that they had conducted many hundreds
of network meta-analyses, but the results were published
for only a small minority. Among the contracting com-
panies that replied to our second survey, there was an
intent to publish about half of the meta-analyses in the
peer-reviewed literature and some others have been used
for HTA submissions. Unwillingness of the industry
sponsor to allow publication was the most common spe-
cified reason for lack of a plan for publication. Registra-
tion of meta-analysis protocols was found to be poor.
To our knowledge, this is the first effort to investigate
the number of network meta-analyses performed by con-
tracting companies commissioned by the industry. There
are, however, some limitations to our study. First, the
response rate of the addressees was 40%. This is probably
acceptable given the involvement of rather sensitive
information [8]. Probably many non-responders did not
actually perform network meta-analysis. Second, since 4
companies out of the 37 that responded were unable to
provide information due to confidentiality agreements
with industry, it is possible that some other companies did
not respond at all for this same reason. Nevertheless, the
19 companies that did perform network meta-analyses
were responsible for the majority of all published network
meta-analyses affiliated with a contracting company,
therefore probably we did capture most of the main stake-
holders operating in this field. The 74 published network
meta-analyses for which no company replied to our first
survey were affiliated to 48 different contracting compan-
ies, indicating that the non-responders had published few
network meta-analyses each and were either less involved
in this type of work and/or had more prominent non-
publication rates than the responders. Third, the accuracy
of the information provided by survey responders cannot
be fully verified. Juxtaposition against verifiable informa-
tion, e.g., number of published papers, suggested mostly
good concordance, but we cannot verify information on
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unpublished work and the reasons for its lack of
publication.
So far, evidence for non-publication in evidence-
based medicine has focused primarily on randomized
trials rather than meta-analyses. Low publication rates
have been found for randomized clinical trials in
many fields, [9–13] and specifically in industry-
sponsored trials [9, 10, 12]. Industry-sponsored trials
that did get published have been shown to more
often find a treatment effect in benefit of the spon-
sor’s treatment [14, 15]. Additionally, examples exist
of intentional withholding of trial reports from publication
due to results not in favor of the sponsor’s drug [16]. This
may also apply to network meta-analyses. Sponsors may
know the outcomes where their drugs rank high and ask
for a network meta-analysis on these outcomes. Further-
more, contracting companies have no incentive to spend
resources on analyzing outcomes other than the ones
requested. There is also a high risk of presenting results in
a way that favors the sponsor’s drug. Further challenges
may arise when publically unavailable data is included in
meta-analyses initiated by industry.
In our study, veto from the industry was the most
common specific stated reason for not having a plan for
publication of network meta-analyses. Moreover, a sub-
stantial number of meta-analyses were left with unclear
reasons for non-publication even among the responders,
so the proportion of these evidence syntheses that were
not published because of the unwillingness of the indus-
try sponsor may be higher. Especially, considering that
the six contracting companies responsible for two-thirds
of all conducted network meta-analyses did not provide
reasons for non-publication. It is unknown whether the
decision for non-publication was made before or after
seeing the results and thus whether non-publication
reflects the presence of unfavorable results for the man-
ufacturers, unwillingness to share with the public (and
thus also with competitors) private information with
strategic advantages, or low priority for publishing meta-
analyses on topics already covered in other published
papers [17]. In general, we think it is safe to state that
publication of any type of analysis done for industry can-
not be separated from the overall commercial strategy
and is not usually done with the aim of disseminating
generalizable knowledge.
Moreover, contracting companies that are commis-
sioned to perform network meta-analyses do not neces-
sarily have strong incentives to publish the results, even
without any veto from the industry sponsor. Contractors
may not have the “publish or perish” pressure that is
typical of academic investigators. Manuscript prepar-
ation and publication also require resources that a
profit-oriented business may not want to spend. Lack of
peer-reviewed publication has been seen also in other
areas of biomedical investigation where entrepreneurs
are involved for profit and has been termed stealth
research [18]. In fact, we identified very few published
network meta-analyses where contracting companies
were the only type of affiliation. The majority of those
published had also academic affiliations which would
offer a traditional motivation for pursuing publication.
Some network meta-analyses that were not published
in the peer-reviewed journal literature were part of an
HTA submission to regulatory agencies like NICE or the
Canadian Agency for Drugs and Technologies in
Health (CADTH). Nevertheless, these submissions
generally only present selected results, while specific
details are sent to the agency separately, thereby mak-
ing it very difficult to assess the rigor and validity of
the network meta-analysis and its results. Similarly,
some pharmaceutical companies may publish their
results on websites or at conferences, but again, judg-
ing the quality and inclusiveness of the analyses is
difficult.
Non-transparency is further compounded by lack of
protocol registration. The percentage of protocol registra-
tion was low, especially when you consider that close to
400 network meta-analysis protocols and more than
12,000 systematic review and/or meta-analysis protocols
have been registered on PROSPERO. Prospective registra-
tion of systematic reviews with written protocols [6, 7] is
increasingly endorsed [19]. The Cochrane Comparing
Multiple Interventions Methods Group (CMIMG) has de-
veloped protocol templates and has made these protocols
available on their website [20]. Protocol registration will
not avoid the need for unanticipated deviations from the
protocol, but would make deviations more visible and
open to public judgment [21, 22].
We did not try to estimate the volume of traditional
systematic reviews and pairwise meta-analyses con-
ducted and/or published by contractors, but this is also
likely to be impressive. Our survey clearly shows there is
a huge market for evidence synthesis, even for the most
sophisticated type of synthesis method. A large segment
of this work happens outside of peer-reviewed publica-
tions, with results only known to contractors and their
sponsors.
Non-publication of network meta-analysis results seems
particularly problematic as network meta-analysis is an evi-
dence synthesis technique that allows informing health
policy and guidelines. Regardless of the exact reasons, non-
publication results in a largely non-transparent corpus of
evidence synthesis work that would otherwise have been of
potential value to patients, clinicians and guideline devel-
opers, and even the industry itself. Reimbursement agen-
cies may require industry to preregister a protocol, e.g., in
PROSPERO, before accepting their HTA submissions.
Another way to improve publication rates may come from
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regulatory bodies that could require certain information
about the HTA submission to be made publically available,
similar to the transparent reporting for systematic reviews
and meta-analyses (PRISMA) extension for network meta-
analyses (PRISMA-NMA standards [23]).
Conclusions
There is a prolific sector of professional contracting
companies that perform network meta-analyses. Industry
commissions many network meta-analyses, but most are
not registered before or published after analyses in the
scientific literature. Mechanisms to improve publication
rates of network meta-analysis commissioned by indus-
try are warranted.
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